Skip to main navigation
Skip to search
Skip to main content
University of Edinburgh Research Explorer Home
Help & FAQ
Home
Research output
Profiles
Research units
Projects
Datasets
Prizes
Activities
Press/Media
Equipment
Search by expertise, name or affiliation
Oral vasodilators for primary Raynaud's phenomenon
B Vinjar,
M Stewart
Deanery of Clinical Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Oral vasodilators for primary Raynaud's phenomenon'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Raynaud Phenomenon
100%
Vasodilator Agent
100%
Chemotherapeutic Agent
83%
Drug
83%
Randomized Controlled Trial
50%
Moxisylyte
33%
Adverse Event
33%
Calcium Channel Blocking Agent
33%
Beraprost
33%
Captopril
33%
Dazoxiben
16%
Therapeutic Procedure
16%
Symptomatic Treatment
16%
Symptom
16%
Accuracy
16%
Buflomedil
16%
Analysis
16%
Multiple Sclerosis
16%
Ketanserin
16%
Peripheral Vascular Disease
16%
Enalapril
16%
Rest
16%
Drug Therapy
16%
Nursing and Health Professions
Raynaud Phenomenon
100%
Vasodilator Agent
100%
Drug
83%
Placebo
50%
Calcium Channel Blocking Agent
33%
Captopril
33%
Moxisylyte
33%
Beraprost
33%
Adverse Event
33%
Data Extraction
16%
Palliative Therapy
16%
Sample Size
16%
Symptom
16%
Ketanserin
16%
Peripheral Vascular Disease
16%
Enalapril
16%
Analysis
16%
Dazoxiben
16%
Missing Data
16%
Multiple Sclerosis
16%
Drug Therapy
16%
Buflomedil
16%
Cochrane Library
16%
Pharmacology, Toxicology and Pharmaceutical Science
Vasodilator Agent
100%
Raynaud Phenomenon
100%
Placebo
100%
Drug
83%
Calcium Channel Blocker
66%
Adverse Event
33%
Moxisylyte
33%
Beraprost
33%
Captopril
33%
Buflomedil
16%
Symptom
16%
Ketanserin
16%
Peripheral Vascular Disease
16%
Dazoxiben
16%
Enalapril
16%
Multiple Sclerosis
16%
Biochemistry, Genetics and Molecular Biology
Captopril
33%
Beraprost
33%
Sample Size
16%
Language
16%
Data Extraction
16%
Accuracy
16%
Cochrane Library
16%
Ketanserin
16%
Rest
16%